Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD versus PAD induction therapy for newly diagnosed multiple myeloma
ChiCTR1900021558Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jul 2016
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lenalidomide and bortezomib in multiple myeloma (MM) (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Efficacy, Side effects and 1 more. Started Jul 2016; status: recruiting.
02
Drugs
lenalidomidebortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR1900021558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021558.